Inovio and Beijing Advaccine to advance vaccine against Coronavirus

30 Jan 2020

Agreement will facilitate clinical trial translations in China.

Inovio Pharmaceuticals is collaborating with Beijing Advaccine Biotechnology to advance the development in China of INO-4800, Inovio's vaccine against the recently emerged strain of coronavirus (2019-nCoV) that has killed numerous people and infected thousands more in China to date.

Inovio and Beijing Advaccine to advance vaccine against Coronavirus

Inovio recently announced that it is developing INO-4800 through Phase I human testing in the US to evaluate safety and immunogenicity with the support of an initial grant up to $9 million from the Coalition for Epidemic Preparedness Innovations (CEPI).

Inovio plans to rapidly develop INO-4800 against the new coronavirus and has already started preclinical testing and preparations for clinical product manufacturing. The goal of this collaboration is to leverage Advaccine's expertise to run a Phase I trial in China in parallel with Inovio's clinical development efforts in the US. Inovio and Advaccine will also work together to attract additional grant funding and further collaborations with larger vaccine companies in China to increase the speed of future testing of INO-4800.

Dr J. Joseph Kim, Inovio's President & CEO, said: "Our collaboration with Beijing Advaccine and its Founder, Emeritus Professor Bin Wang from the prestigious Fudan University and China's premier DNA vaccine expert, will tremendously accelerate our coronavirus vaccine INO-4800 development in China because of its expertise and experience with regulatory authorities and clinical trial management. This collaboration allows us to enter China and deliver our vaccine into the areas where they need it most as soon as possible. Our shared goal is to utilize both companies' expertise in developing vaccines for emerging infectious diseases and hopefully achieve an accelerated regulatory approval for INO-4800."

Inovio's participation in this developing effort is based on the ideal suitability of its DNA medicine platform to rapidly develop vaccines against emerging viruses with pandemic potential, proven vaccine development capabilities, and a strong track record of rapidly generating promising countermeasures against previous pandemic threats. Inovio was the first to advance its vaccine (INO-4700) against MERS-CoV, a related coronavirus, into evaluation in humans. Inovio is currently preparing to initiate a Phase II trial for INO-4700 in the Middle East where most MERS viral outbreaks have occurred. Those efforts are supported by CEPI funding and partnership.

In a recently published paper in Lancet Infectious Diseases, Inovio's Phase I study of INO-4700, its MERS-CoV vaccine, demonstrated it was well-tolerated and furthermore induced high levels of antibody responses in approximately 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Durable antibody responses to INO-4700 were also maintained through 60 weeks following dosing.

Read More

Related news

iNova Pharmaceuticals announces the launch of iPitch 2020

iNova Pharmaceuticals announces the launch of iPitch 2020

3 Jul 2020

Following on from the success of the inaugural iPitch launch in 2019, iNova Pharmaceuticals is delighted to announce the launch of a new round of iPitch challenges for 2020.

Read more 
Pharma packaging companies commit to supply for COVID-19 fight

Pharma packaging companies commit to supply for COVID-19 fight

16 Jun 2020

Stevanato Group, SCHOTT, and Gerresheimer confirm their readiness to support future COVID-19 vaccine with pharmaceutical containers.

Read more 
Emergent bags $628 million landmark CDMO deal to produce COVID-19 vaccine candidates

Emergent bags $628 million "landmark" CDMO deal to produce COVID-19 vaccine candidates

2 Jun 2020

The company will provide CDMO capabilities, capacities, and expertise to support the US government’s Warp Speed Program to pave the way for innovators to advance COVID-19 programs.

Read more 
India says shipments of hydroxychloroquine will resume after US exerts pressure

India says shipments of hydroxychloroquine will resume after US exerts pressure

7 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
Chinese CDMOs legislating for the future

Chinese CDMOs legislating for the future

2 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
FDA orders ranitidine withdrawal due to nitrosamine contamination risk

FDA orders ranitidine withdrawal due to nitrosamine contamination risk

2 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
China focused on meeting international API demand amid pandemic, say officials

China focused on meeting international API demand amid pandemic, say officials

1 Apr 2020

Our content has now moved to our new Global Pharma Insights website, providing the very latest news and information covering all aspects of the pharmaceutical supply chain. Please click the link below to access this article.

Read more 
CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

CDMO Suven’s finished drug exports halted due to Indian COVID-19 lockdown

25 Mar 2020

Indian contract development and manufacturing organisation, Suven Pharmaceuticals, has warned it cannot export finished products due to a shortage of raw materials following the country’s recent lockdown to fight the COVID-19 pandemic.

Read more 
2020 - a year for 'big answers' rather than 'big data'

2020 - a year for 'big answers' rather than 'big data'

7 Feb 2020

Zenith Technologies CEO, Joe Haugh, takes us through how the business has evolved this year, to better meet the needs of its customers, as well as the trends they see shaping the industry through 2020 and beyond.

Read more 
AstraZeneca embarks on $1bn zero carbon strategy

AstraZeneca embarks on $1bn zero carbon strategy

24 Jan 2020

The programme will include the launch of next-generation respiratory inhalers, which will use near-zero Global Warming Potential propellants.

Read more